Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome

Efe, Cumali; Ozaslan, Ersan; KAV, TAYLAN; Purnak, TUĞRUL; Shorbagi, Ali; ÖZKAYAR, ÖZGÜR; Berlot, Alexandra; SÖKMENSÜER, CENK; Muratori, Paolo

doi:10.1016/j.autrev.2011.09.006

Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome

Efe C., Ozaslan E., KAV T., Purnak T., Shorbagi A., ÖZKAYAR Ö., ...Daha Fazla

AUTOIMMUNITY REVIEWS, cilt.11, sa.5, ss.330-334, 2012 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Derleme
Cilt numarası: 11 Sayı: 5
Basım Tarihi: 2012
Doi Numarası: 10.1016/j.autrev.2011.09.006
Dergi Adı: AUTOIMMUNITY REVIEWS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.330-334
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Hacettepe Üniversitesi Adresli: Evet

Özet

Background and aim: The aim of the present study was to assess the efficacy and tolerability of budesonide as an alternative first line treatment option for autoimmune hepatitis (AIH) and the overlap syndrome.